FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3103296817> ?p ?o ?g. }

• W3103296817 endingPage "100236" @default.
• W3103296817 startingPage "100236" @default.
• W3103296817 abstract "There are limited population-based studies of hairy cell leukemia (HCL), a rare chronic lymphoproliferative disorder of B-cells. We conducted a population-based study that included all patients diagnosed with HCL between 1996 and 2016 in Western Normandy. Recorded data focused on medical history, clinical presentation, biological results, treatment modalities in the first line and in relapsed/refractory patients and the occurrence of secondary malignancies. One hundred and twenty-three HCL patients were registered in the database. HCL represented 0.7% of all malignant hematological disorders and 3.0% of all leukemia. The overall age-standardized incidence ratio (SIR) was 0.39/100,000 inhabitants in men and 0.09/100,000 in women, and it remained stable over the 20-year period analyzed. One hundred and seven patients (88%) received first-line treatment, 33 patients (27%) received at least 2 lines of treatment and 14 patients (11%) received more than 2 lines. Cladribine used as first-line treatment induced a high hematological complete response (HCR) rate of 92%. The median overall survival (OS) was over 15 years, with 5-year and 10-year survival rates of 84% and 70.5%. No significant differences in OS were observed between men and women, between the calendar periods studied or between patients who received a single line treatment with IFN-α or PNA. The risk of relapse was higher with IFN-α treatment, requiring subsequent treatments in that patients. The time to next treatment (TTN) tends to be longer for PNAs compared to IFN-α even if difference is not significant. Secondary cancers were observed in 9/123 patients (7.3%) with solid tumors in 8 patients and hematological malignancy in one patient. Our data confirm in real life that single courses of cladribine administered to patients with HCL induce high response rates, the majority of which are HCR. Relapses seem less frequent than with IFN-α and the administration schedule is less restrictive for the patients. The emergence of chemo-immunotherapy and the development of effective new drugs such as recombinant immunotoxins and BRAF targeting will offer new possibilities in the management of HCL patients." @default.
• W3103296817 created "2020-11-23" @default.
• W3103296817 creator A5005723723 @default.
• W3103296817 creator A5048097062 @default.
• W3103296817 creator A5050036716 @default.
• W3103296817 creator A5062422990 @default.
• W3103296817 creator A5069332175 @default.
• W3103296817 creator A5079460037 @default.
• W3103296817 creator A5081871516 @default.
• W3103296817 date "2020-01-01" @default.
• W3103296817 modified "2023-10-16" @default.
• W3103296817 title "A population-based study of hairy cell leukemia over a period of 20 years" @default.
• W3103296817 cites W1939042877 @default.
• W3103296817 cites W1981766288 @default.
• W3103296817 cites W1991265790 @default.
• W3103296817 cites W1995628336 @default.
• W3103296817 cites W2002246616 @default.
• W3103296817 cites W2004019800 @default.
• W3103296817 cites W2008979857 @default.
• W3103296817 cites W2011720767 @default.
• W3103296817 cites W2018107416 @default.
• W3103296817 cites W2039070967 @default.
• W3103296817 cites W2040600539 @default.
• W3103296817 cites W2050722799 @default.
• W3103296817 cites W2057731311 @default.
• W3103296817 cites W2081139525 @default.
• W3103296817 cites W2086317830 @default.
• W3103296817 cites W2088299237 @default.
• W3103296817 cites W2099780734 @default.
• W3103296817 cites W2100618615 @default.
• W3103296817 cites W2123052393 @default.
• W3103296817 cites W2147612943 @default.
• W3103296817 cites W2150246633 @default.
• W3103296817 cites W2244152503 @default.
• W3103296817 cites W2314659489 @default.
• W3103296817 cites W2409184875 @default.
• W3103296817 cites W2558871324 @default.
• W3103296817 cites W2767975446 @default.
• W3103296817 cites W2786358992 @default.
• W3103296817 cites W2899539950 @default.
• W3103296817 cites W2913070721 @default.
• W3103296817 cites W2948959744 @default.
• W3103296817 cites W78071506 @default.
• W3103296817 doi "https://doi.org/10.1016/j.ctarc.2020.100236" @default.
• W3103296817 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33227559" @default.
• W3103296817 hasPublicationYear "2020" @default.
• W3103296817 type Work @default.
• W3103296817 sameAs 3103296817 @default.
• W3103296817 citedByCount "6" @default.
• W3103296817 countsByYear W31032968172021 @default.
• W3103296817 countsByYear W31032968172022 @default.
• W3103296817 countsByYear W31032968172023 @default.
• W3103296817 crossrefType "journal-article" @default.
• W3103296817 hasAuthorship W3103296817A5005723723 @default.
• W3103296817 hasAuthorship W3103296817A5048097062 @default.
• W3103296817 hasAuthorship W3103296817A5050036716 @default.
• W3103296817 hasAuthorship W3103296817A5062422990 @default.
• W3103296817 hasAuthorship W3103296817A5069332175 @default.
• W3103296817 hasAuthorship W3103296817A5079460037 @default.
• W3103296817 hasAuthorship W3103296817A5081871516 @default.
• W3103296817 hasBestOaLocation W31032968171 @default.
• W3103296817 hasConcept C120665830 @default.
• W3103296817 hasConcept C121332964 @default.
• W3103296817 hasConcept C126322002 @default.
• W3103296817 hasConcept C142424586 @default.
• W3103296817 hasConcept C187212893 @default.
• W3103296817 hasConcept C2778461978 @default.
• W3103296817 hasConcept C2779200787 @default.
• W3103296817 hasConcept C2780483514 @default.
• W3103296817 hasConcept C2908647359 @default.
• W3103296817 hasConcept C61511704 @default.
• W3103296817 hasConcept C71924100 @default.
• W3103296817 hasConcept C87355193 @default.
• W3103296817 hasConcept C99454951 @default.
• W3103296817 hasConceptScore W3103296817C120665830 @default.
• W3103296817 hasConceptScore W3103296817C121332964 @default.
• W3103296817 hasConceptScore W3103296817C126322002 @default.
• W3103296817 hasConceptScore W3103296817C142424586 @default.
• W3103296817 hasConceptScore W3103296817C187212893 @default.
• W3103296817 hasConceptScore W3103296817C2778461978 @default.
• W3103296817 hasConceptScore W3103296817C2779200787 @default.
• W3103296817 hasConceptScore W3103296817C2780483514 @default.
• W3103296817 hasConceptScore W3103296817C2908647359 @default.
• W3103296817 hasConceptScore W3103296817C61511704 @default.
• W3103296817 hasConceptScore W3103296817C71924100 @default.
• W3103296817 hasConceptScore W3103296817C87355193 @default.
• W3103296817 hasConceptScore W3103296817C99454951 @default.
• W3103296817 hasLocation W31032968171 @default.
• W3103296817 hasLocation W31032968172 @default.
• W3103296817 hasLocation W31032968173 @default.
• W3103296817 hasLocation W31032968174 @default.
• W3103296817 hasLocation W31032968175 @default.
• W3103296817 hasLocation W31032968176 @default.
• W3103296817 hasOpenAccess W3103296817 @default.
• W3103296817 hasPrimaryLocation W31032968171 @default.
• W3103296817 hasRelatedWork W1969613249 @default.
• W3103296817 hasRelatedWork W1987154737 @default.
• W3103296817 hasRelatedWork W2004057124 @default.

• next